Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Promising Data From Selinexor Plus Pd in Myeloma Spur Combo to Phase 3 Trial
December 8th 2020Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.
Venetoclax/Rituximab Combo Demonstrates Sustained Benefit for Retreated Patients with CLL
December 8th 2020December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.
Pevonedistat/Azacitidine Demonstrates Improved Efficacy Vs Single-Agent Azacitidine in MDS
December 8th 2020December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.
Driver Mutations Detectable in Utero, Used to Calculate MPN Diagnosis
December 8th 2020JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.
Asciminib Significantly Improves Major Molecular Response in Pretreated Chronic Phase-CML
Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.
LOXO-305 Elicits Impressive Responses in Previously Treated CLL/SLL
LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure
December 8th 2020December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.
Liso-Cel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL
December 8th 2020December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses
Daratumumab Quadruplet Improves Hematologic CR Rate in AL Amyloidosis
December 7th 2020December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.
Encouraging Efficacy Shown With Luspatercept in MDS/MPN-RS-T
December 7th 2020December 7, 2020 — Findings from the MEDALIST trial demonstrated encouraging clinical efficacy, as well as a tolerable safety profile, with luspatercept among patients with myelodysplastic syndrome and myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Survival Following Post–HCT Relapse in ALL Improves With Targeted Immunotherapies
December 7th 2020December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.
All-Oral Ixazomib Triplet Improves PFS in Select Transplant-Ineligible Newly Diagnosed Myeloma
December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.
Ublituximab/Umbralisib Outperforms Chemoimmunotherapy in Patients with CLL
December 7th 2020December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.
Negrin Shines Light on the Orca-T Story in GVHD
What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.
Glofitamab Demonstrates High CR Rate in Relapsed/Refractory NHL
December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.
Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma
December 7th 2020December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.
CELMoD CC-92480/Dexamethasone Combo Shows Early Activity in Relapsed/Refractory Myeloma
December 6th 2020CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.
Cilta-Cel Improves HRQoL in Relapsed/Refractory Multiple Myeloma
December 6th 2020Ciltacabtagene autoleucel was found to elicit clinically meaningful improvements in health-related quality of life in patients with relapsed/refractory multiple myeloma, and this benefit may become even more pronounced as responses to treatment deepen over time, according to data from the CARTITUDE-1 study presented during the 2020 ASH Annual Meeting & Exposition.
Sabatolimab Showcases Similar Pharmacokinetics Across 400- and 800-mg Doses in MDS/AML
December 6th 2020Sabatolimab demonstrated comparable pharmacokinetic activity at doses of 200 mg every 2 weeks and 800 mg every 4 weeks in combination with hypomethylating agents in patients with acute myeloid leukemia and myelodysplastic syndrome.
